Skip to content

Children With Congenital Diaphragmatic Hernia and the Quality of Their Daily Lives

Children With Congenital Diaphragmatic Hernia and the Quality of Their Daily Lives

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07432672
Enrollment
80
Registered
2026-02-25
Start date
2023-05-01
Completion date
2025-07-01
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Diaphragmatic Hernia

Keywords

Quality of life

Brief summary

Background: Congenital diaphragmatic hernia is a rare disease, resulting from a developmental malformation of the diaphragm. Over the last years, management of the affected children has improved significantly. Despite progress in the treatment, it is still related to a high mortality rate. After birth, congenital diaphragmatic hernias are associated with lung hypoplasia as well as pulmonary hypertension which can in turn lead to cardiac dysfunction. Comorbidities as gastroesophageal reflux or respiratory difficulties, such as chronic pulmonary symptoms or repeated respiratory tract infections are common amongst survivors. However, little is known about the health-related quality of life in children after surgical intervention of their diaphragm. Aim: This study aims to obtain information on the health-related quality of life in children with congenital diaphragmatic hernia to improve their future long-term management. Methods: A single-centre prospective study was conducted, examining health-related quality of life of children between five and 18 years of age who were initially treated at the General Hospital of Vienna for congenital diaphragmatic hernia between 2005 and 2019. The validated KIDSCREEN-27 questionnaire was used to assess the health-related quality of life of children with a congenital diaphragmatic hernia, completed by the whole family, including the affected child himself (≥ 8 years old), parents, and siblings. Additionally, a detailed demographic review was obtained.

Interventions

None listed

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* In this study, patients diagnosed with CDH, born between 2005 and 2019 and treated at the Medical University of Vienna at the Comprehensive Center for Pediatrics were included after giving their written consent for this study. Children with CDH, at least eight years old, their parents, and siblings (eight years or older) were asked to complete the questionnaire. * CDH patients answered the KIDSCREEN-27 childrens version questionnaire (see Appendix) if they were aged eight to 18 years. * Parents answered the KIDSCREEN-27 parents version questionnaire (see Appendix). If the CDH patients were younger than eight years, only their parents were asked to fill out the questionnaire. * If siblings were at least eight years old, they were also asked to complete a questionnaire, which is a newly created version of the KIDSCREEN-27 parents version concerning the quality of life of their CDH affected siblings (see Appendix).

Exclusion criteria

* Missing written informed consent to the study from the CDH patient, parents, or siblings led to exclusion. Parents and siblings of deceased patients were not included.

Design outcomes

Primary

MeasureTime frameDescription
Primary Outcome Measure2023-2025Primary outcome of this study was HRQoL, assessed using the KIDSCREEN-27 questionnaire . It consists of 27 items covering 5 dimensions (Physical and Psychological Well-Being, Autonomy \& Parent Relations, Social Support \& Peers, and School Environment). Raw scores are transformed into T-scores with a mean of 50 and a standard deviation of 10 based on European normative data. Higher scores indicate better HRQoL. Self- and proxy-reported HRQoL were compared among CDH patients, parents, and siblings. Statistical analyses were performed using SPSS©(V 29.0.2.0), Microsoft Excel© (V16.98), and R (V 4.4.2). Two-sided p-values \<0.05 were considered statistically significant. Continuous variables are presented as mean±standard deviation or median (range), and categorical variables as percentages, based on the number of valid observations (N valid). Group comparisons were conducted using the chi-square test for categorical variables and the two-tailed unpaired t-test for continuous variables.

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026